AUBAGIO

Reason for request

Clinical Benefit

Substantial

Substancial

Clinical Added Value

no clinical added value

In the absence of a conclusive comparative study versus active treatment, AUBAGIO does not provide an improvement in actual benefit (IAB V, non-existent) in the treatment of relapsing-remitting multiple sclerosis (RRMS). However, the Transparency Committee recognises the benefit of providing an oral proprietary medicinal product as an alternative to interferon beta and glatiramer acetate.